Azor cleared for first-line use in the US
This article was originally published in Scrip
Executive Summary
The US FDA has approved Daiichi Sankyo's combination antihypertensive Azor for first-line use. The once-daily single pill contains the angiotensin II antagonist olmesartan medoxomil and the calcium antagonist amlodipine.